Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance.
Kuilman MM, Ellappalayam A, Barcaru A, Haan JC, Bhaskaran R, Wehkamp D, Menicucci AR, Audeh WM, Mittempergher L, Glas AM. Kuilman MM, et al. Among authors: mittempergher l. Breast Cancer Res Treat. 2022 Oct;195(3):263-274. doi: 10.1007/s10549-022-06698-x. Epub 2022 Aug 19. Breast Cancer Res Treat. 2022. PMID: 35984580 Free PMC article.
B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
Steenbruggen TG, Wolf DM, Campbell MJ, Sanders J, Cornelissen S, Thijssen B, Salgado RA, Yau C, O-Grady N, Basu A, Bhaskaran R, Mittempergher L, Hirst GL, Coppe JP, Kok M, Sonke GS, van 't Veer LJ, Horlings HM. Steenbruggen TG, et al. Among authors: mittempergher l. Breast Cancer Res. 2023 Oct 4;25(1):117. doi: 10.1186/s13058-023-01717-1. Breast Cancer Res. 2023. PMID: 37794508 Free PMC article.
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.
Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, Sotiriou C, Fumagalli D, Jimenez J, Aura C, Prudkin L, Díaz-Delgado MC, de la Peña L, Loi S, Ellis C, Schultz N, de Azambuja E, Harbeck N, Piccart-Gebhart M, Bernards R, Baselga J. Majewski IJ, et al. Among authors: mittempergher l. J Clin Oncol. 2015 Apr 20;33(12):1334-9. doi: 10.1200/JCO.2014.55.2158. Epub 2015 Jan 5. J Clin Oncol. 2015. PMID: 25559818 Free PMC article. Clinical Trial.
MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology.
Mittempergher L, Delahaye LJMJ, Witteveen AT, Spangler JB, Hassenmahomed F, Mee S, Mahmoudi S, Chen J, Bao S, Snel MHJ, Leidelmeijer S, Besseling N, Bergstrom Lucas A, Pabón-Peña C, Linn SC, Dreezen C, Wehkamp D, Chan BY, Bernards R, van 't Veer LJ, Glas AM. Mittempergher L, et al. J Mol Diagn. 2019 Sep;21(5):808-823. doi: 10.1016/j.jmoldx.2019.04.007. Epub 2019 Jun 4. J Mol Diagn. 2019. PMID: 31173928 Free article.
Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis.
Schlicker A, Ellappalayam A, Beumer IJ, Snel MHJ, Mittempergher L, Diosdado B, Dreezen C, Tian S, Salazar R, Loupakis F, Pietrantonio F, Santos Vivas C, Martinez-Villacampa MM, Villanueva A, Sanjuán X, Schirripa M, Fassan M, Martinetti A, Fucà G, Lonardi S, Keilholz U, Glas AM, Bernards R, Vecchione L. Schlicker A, et al. Among authors: mittempergher l. Int J Cancer. 2020 Oct 15;147(8):2303-2315. doi: 10.1002/ijc.33003. Epub 2020 Apr 24. Int J Cancer. 2020. PMID: 32270478 Free article.
27 results